• Debiopharm Group, of Lausanne, Switzerland, treated its first patient in an open-label, Phase III trial of triptorelin pamoate 22.5 mg 6-month formulation in children with central precocious puberty. The study will enroll 44 children from the U.S., Chile and Mexico, with a primary objective of evaluating safety and efficacy in reducing luteinizing hormone to prepubertal levels after six months.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-855-260-5607
Outside the U.S.: 1-646-822-4549
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter